MiProstate - Information Hub for the Prostate Cancer Care Flow
NCT05239377 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1329
Last updated 2022-02-14
Summary
This is an observational cohort study with a non-concurrent comparison group evaluating the use of a digital decision support tool (MiProstate/ISPM) at pre-prostatectomy, multidisciplinary conferences.
Conditions
Interventions
- OTHER
-
IntelliSpace Precision Medicine Multidisciplinary Team Orchestrator
Digital decision support
Sponsors & Collaborators
-
Philips Electronics Nederland B.V. acting through Philips CTO organization
collaborator INDUSTRY -
Karolinska University Hospital
lead OTHER
Principal Investigators
-
Olof Akre, MD,Professor · Karolinska University Hospital, Dept of Pelvic Cancer
Eligibility
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-02-21
- Primary Completion
- 2021-06-01
- Completion
- 2021-12-10
Countries
- Sweden
Study Locations
More Related Trials
-
Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide
NCT02312557 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
NCT06551324 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
imPlementing ROutine Molecular Characterization in Patients With Metastatic Castration Resistant ProstaTe Cancer by NGS
NCT04746300 ·Status: UNKNOWN
-
A Phase I Pilot Study Comparing 123I MIP 1072 Versus 111In Capromab Pendetide in Subjects With Metastatic Prostate Cancer
NCT00992745 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy
NCT05919329 ·Status: RECRUITING ·Phase: PHASE4
-
Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
NCT04946370 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer
NCT05534646 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199)
NCT02787005 ·Status: COMPLETED ·Phase: PHASE2
-
T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer
NCT02113657 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
NCT03151629 ·Status: RECRUITING
-
A Safety and Feasibility Study of Mitotane in Prostate Cancer
NCT02057237 ·Status: COMPLETED ·Phase: PHASE1
-
Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer
NCT02012296 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer
NCT04717154 ·Status: COMPLETED ·Phase: PHASE2
-
Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer
NCT00170157 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer
NCT03674814 ·Status: COMPLETED ·Phase: PHASE1
-
Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer
NCT01133704 ·Status: COMPLETED ·Phase: PHASE3
-
A Registry to Observe the Treatment of Prostate Cancer Under Routine Medical Care
NCT02236637 ·Status: COMPLETED
-
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
NCT06145633 ·Status: RECRUITING ·Phase: PHASE2
-
To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen
NCT00715078 ·Status: COMPLETED ·Phase: PHASE2
-
Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise Testing
NCT02353715 ·Status: COMPLETED
-
Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate Cancer
NCT00058539 ·Status: COMPLETED ·Phase: PHASE2
-
Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT
NCT03007732 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT01695044 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
NCT02861573 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
To Live Better After Prostate Cancer Treatment:
NCT05100121 ·Status: RECRUITING ·Phase: NA